Liraglutide (Saxenda) vs orforglipron

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Liraglutide (Saxenda)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT00781937 · Phase 3 · completed

The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.

Next expected readout: December 2026 · NCT07225816 (registry estimate)

Reported efficacy

Change in BMI SDS (Week 0, Week 56): Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) (met)

Result source: NCT02918279

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Approved in Obesitysmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: February 2027 · NCT06672549 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Saxenda)orforglipron
Body weight, % change-8.0% vs -2.6%−5.4 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
20 other results
  • -6.1% vs -0.1% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • -5.9% vs -2% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • -4.6% vs -2% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • -7.7% vs -6.5% wk 12 · n 93 · Phase 3 · primary NCT03374956
  • -6.1% vs -1.9% 3.0 mg · wk 160 · n 1467 · Phase 3 · secondary NCT01272219
  • 0.7% vs 0.3% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • 2.9% vs 0.3% 3.0 mg · wk 68 · n 346 · Phase 3 · secondary NCT01272219
  • -8.4% vs -3.1% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • -6.8% vs -3.1% 3.0 mg · wk 68 · n 347 · Phase 3 · secondary NCT01272219
  • -4.7% vs -2.7% 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -3.6% vs -2.7% 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -5.7% vs -1.4% 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -0.4% vs 3.3% wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 6.3% vs 3.3% wk 52 · n 14 · Phase 3 · secondary NCT02527200
  • 2.6% vs 3.3% wk 52 · n 31 · Phase 3 · secondary NCT02527200
  • -1.7% vs -1.2% wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -1.1% vs -1.2% wk 16 · n 16 · Phase 3 · secondary NCT02527200
  • -1.4% vs -1.2% wk 16 · n 34 · Phase 3 · secondary NCT02527200
  • -3.3% vs 0.2% wk 40 · n 29 · Phase 2 · primary NCT03158805
  • -6.6% vs -1.2% 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
-7.9% vs -0.6%−7.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
11 other results
  • -8.7% vs -0.6% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • -5.9% vs -0.6% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • -12.3% vs -2% 36 mg · wk 26 · n 56 · Phase 2 · primary NCT05051579
  • -8.6% vs -2% 12 mg · wk 26 · n 44 · Phase 2 · primary NCT05051579
  • -12.6% vs -2% 45 mg · wk 26 · n 57 · Phase 2 · primary NCT05051579
  • -11.2% vs -2% 24 mg · wk 26 · n 51 · Phase 2 · primary NCT05051579
  • -13.5% vs -2.3% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • -9.4% vs -2.3% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • -14.7% vs -2.3% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.5% vs -2.3% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • -9.6% vs -2.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
Weight loss of 5% or more63.2% vs 27.1%+36.1 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
4 other results
  • 50.5% vs 21.9% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • 49.9% vs 13.8% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 35.6% vs 13.8% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 76% vs 17% wk 52 · n 58 · Phase 4 · primary NCT03048578
58.3% vs 15%+43.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 61.4% vs 15% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • 45.9% vs 15% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • 92.0% vs 24.0% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 89.5% vs 22.9% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 72% vs 24.0% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 74.4% vs 22.9% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 90.4% vs 24.0% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 87.3% vs 22.9% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 89.5% vs 24.0% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 88.8% vs 22.9% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
Weight loss of 10% or more33.1% vs 10.6%+22.5 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
3 other results
  • 23.4% vs 4.3% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 14.4% vs 4.3% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 26.1% vs 6.3% 3.0 mg · wk 56 · n 194 · Phase 3 · secondary NCT00781937
38.3% vs 3.3%+35 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 35.1% vs 3.3% 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • 18.0% vs 3.3% 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • 74.8% vs 8.8% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 71.3% vs 2.3% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 46.5% vs 8.8% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 39.4% vs 2.3% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 69.1% vs 8.8% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 69.9% vs 2.3% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 61.9% vs 8.8% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 56.6% vs 2.3% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
Waist circumference, change (cm)-6.9 vs -3.4−3.5 vs placebo3.0 mg · wk 160 · n 1472NCT01272219
24 other results
  • -8.2 vs -3.9 3.0 mg · wk 56 · n 2437 · Phase 3 · secondary NCT01272219
  • -5.7 vs -3.2 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -4.4 vs -0.9 3.0 mg · wk 56 · n 207 · Phase 3 · secondary NCT00781937
  • -6.1 vs -2.7 3.0 mg · wk 56 · n 412 · Phase 3 · secondary NCT01272232
  • -4.4 vs -3.2 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -4.8 vs -2.7 1.8 mg · wk 56 · n 204 · Phase 3 · secondary NCT01272232
  • 100.9 vs 109.9 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -3.0 vs -2.1 wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 0.5 vs -2.1 wk 52 · n 13 · Phase 3 · secondary NCT02527200
  • -1.5 vs -2.1 wk 52 · n 30 · Phase 3 · secondary NCT02527200
  • -2.5 vs -1.9 wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -0.7 vs -1.9 wk 16 · n 15 · Phase 3 · secondary NCT02527200
  • -1.7 vs -1.9 wk 16 · n 33 · Phase 3 · secondary NCT02527200
  • -7.4 vs -4.6 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
  • -9.8 vs -9.5 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -7.9 vs -6 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -9 vs -9.5 1.8 mg / 3.0 mg · wk 104 · n 38 · Phase 2 · secondary NCT00422058
  • -5.9 vs -6 1.8 mg / 3.0 mg · wk 20 · n 83 · Phase 2 · secondary NCT00422058
  • -10 vs -9.5 placebo / 2.4 mg / 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -10.4 vs -9.5 2.4 mg / 3.0 mg · wk 104 · n 45 · Phase 2 · secondary NCT00422058
  • -4.2 vs -6 placebo / 2.4 mg / 3.0 mg · wk 20 · n 90 · Phase 2 · secondary NCT00422058
  • -7.2 vs -6 2.4 mg / 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -8.6 vs -9.5 1.2 mg / 3.0 mg · wk 104 · n 46 · Phase 2 · secondary NCT00422058
  • -5.8 vs -6 1.2 mg / 3.0 mg · wk 20 · n 93 · Phase 2 · secondary NCT00422058
-5.7 vs -0.1−5.6 vs placebo36 mg QD · wk 72 · n 60NCT05931380
12 other results
  • -5.9 vs -0.1 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • -3.7 vs -0.1 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • -10.6 vs -4 36 mg · wk 36 · n 52 · Phase 2 · secondary NCT05051579
  • -10.1 vs -3.6 36 mg · wk 26 · n 52 · Phase 2 · secondary NCT05051579
  • -9.6 vs -4 12 mg · wk 36 · n 43 · Phase 2 · secondary NCT05051579
  • -8 vs -3.6 12 mg · wk 26 · n 43 · Phase 2 · secondary NCT05051579
  • -13.6 vs -4 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.2 vs -3.6 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • -11.2 vs -4 24 mg · wk 36 · n 49 · Phase 2 · secondary NCT05051579
  • -8.8 vs -3.6 24 mg · wk 26 · n 49 · Phase 2 · secondary NCT05051579
  • -5.8 n 9 · Phase 1 · secondary NCT06023095
  • -11.7 n 9 · Phase 1 · secondary NCT06023095

Body weight, % change

Liraglutide (Saxenda)
-8.0% vs -2.6%−5.4 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
20 other results
  • -6.1% vs -0.1% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • -5.9% vs -2% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • -4.6% vs -2% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • -7.7% vs -6.5% wk 12 · n 93 · Phase 3 · primary NCT03374956
  • -6.1% vs -1.9% 3.0 mg · wk 160 · n 1467 · Phase 3 · secondary NCT01272219
  • 0.7% vs 0.3% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • 2.9% vs 0.3% 3.0 mg · wk 68 · n 346 · Phase 3 · secondary NCT01272219
  • -8.4% vs -3.1% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • -6.8% vs -3.1% 3.0 mg · wk 68 · n 347 · Phase 3 · secondary NCT01272219
  • -4.7% vs -2.7% 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -3.6% vs -2.7% 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -5.7% vs -1.4% 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -0.4% vs 3.3% wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 6.3% vs 3.3% wk 52 · n 14 · Phase 3 · secondary NCT02527200
  • 2.6% vs 3.3% wk 52 · n 31 · Phase 3 · secondary NCT02527200
  • -1.7% vs -1.2% wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -1.1% vs -1.2% wk 16 · n 16 · Phase 3 · secondary NCT02527200
  • -1.4% vs -1.2% wk 16 · n 34 · Phase 3 · secondary NCT02527200
  • -3.3% vs 0.2% wk 40 · n 29 · Phase 2 · primary NCT03158805
  • -6.6% vs -1.2% 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
orforglipron
-7.9% vs -0.6%−7.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
11 other results
  • -8.7% vs -0.6% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • -5.9% vs -0.6% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • -12.3% vs -2% 36 mg · wk 26 · n 56 · Phase 2 · primary NCT05051579
  • -8.6% vs -2% 12 mg · wk 26 · n 44 · Phase 2 · primary NCT05051579
  • -12.6% vs -2% 45 mg · wk 26 · n 57 · Phase 2 · primary NCT05051579
  • -11.2% vs -2% 24 mg · wk 26 · n 51 · Phase 2 · primary NCT05051579
  • -13.5% vs -2.3% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • -9.4% vs -2.3% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • -14.7% vs -2.3% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.5% vs -2.3% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • -9.6% vs -2.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620

Weight loss of 5% or more

Liraglutide (Saxenda)
63.2% vs 27.1%+36.1 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
4 other results
  • 50.5% vs 21.9% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • 49.9% vs 13.8% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 35.6% vs 13.8% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 76% vs 17% wk 52 · n 58 · Phase 4 · primary NCT03048578
orforglipron
58.3% vs 15%+43.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 61.4% vs 15% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • 45.9% vs 15% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • 92.0% vs 24.0% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 89.5% vs 22.9% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 72% vs 24.0% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 74.4% vs 22.9% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 90.4% vs 24.0% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 87.3% vs 22.9% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 89.5% vs 24.0% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 88.8% vs 22.9% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579

Weight loss of 10% or more

Liraglutide (Saxenda)
33.1% vs 10.6%+22.5 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
3 other results
  • 23.4% vs 4.3% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 14.4% vs 4.3% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 26.1% vs 6.3% 3.0 mg · wk 56 · n 194 · Phase 3 · secondary NCT00781937
orforglipron
38.3% vs 3.3%+35 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 35.1% vs 3.3% 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • 18.0% vs 3.3% 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • 74.8% vs 8.8% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 71.3% vs 2.3% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 46.5% vs 8.8% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 39.4% vs 2.3% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 69.1% vs 8.8% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 69.9% vs 2.3% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 61.9% vs 8.8% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 56.6% vs 2.3% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579

Waist circumference, change (cm)

Liraglutide (Saxenda)
-6.9 vs -3.4−3.5 vs placebo3.0 mg · wk 160 · n 1472NCT01272219
24 other results
  • -8.2 vs -3.9 3.0 mg · wk 56 · n 2437 · Phase 3 · secondary NCT01272219
  • -5.7 vs -3.2 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -4.4 vs -0.9 3.0 mg · wk 56 · n 207 · Phase 3 · secondary NCT00781937
  • -6.1 vs -2.7 3.0 mg · wk 56 · n 412 · Phase 3 · secondary NCT01272232
  • -4.4 vs -3.2 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -4.8 vs -2.7 1.8 mg · wk 56 · n 204 · Phase 3 · secondary NCT01272232
  • 100.9 vs 109.9 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -3.0 vs -2.1 wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 0.5 vs -2.1 wk 52 · n 13 · Phase 3 · secondary NCT02527200
  • -1.5 vs -2.1 wk 52 · n 30 · Phase 3 · secondary NCT02527200
  • -2.5 vs -1.9 wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -0.7 vs -1.9 wk 16 · n 15 · Phase 3 · secondary NCT02527200
  • -1.7 vs -1.9 wk 16 · n 33 · Phase 3 · secondary NCT02527200
  • -7.4 vs -4.6 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
  • -9.8 vs -9.5 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -7.9 vs -6 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -9 vs -9.5 1.8 mg / 3.0 mg · wk 104 · n 38 · Phase 2 · secondary NCT00422058
  • -5.9 vs -6 1.8 mg / 3.0 mg · wk 20 · n 83 · Phase 2 · secondary NCT00422058
  • -10 vs -9.5 placebo / 2.4 mg / 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -10.4 vs -9.5 2.4 mg / 3.0 mg · wk 104 · n 45 · Phase 2 · secondary NCT00422058
  • -4.2 vs -6 placebo / 2.4 mg / 3.0 mg · wk 20 · n 90 · Phase 2 · secondary NCT00422058
  • -7.2 vs -6 2.4 mg / 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -8.6 vs -9.5 1.2 mg / 3.0 mg · wk 104 · n 46 · Phase 2 · secondary NCT00422058
  • -5.8 vs -6 1.2 mg / 3.0 mg · wk 20 · n 93 · Phase 2 · secondary NCT00422058
orforglipron
-5.7 vs -0.1−5.6 vs placebo36 mg QD · wk 72 · n 60NCT05931380
12 other results
  • -5.9 vs -0.1 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • -3.7 vs -0.1 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • -10.6 vs -4 36 mg · wk 36 · n 52 · Phase 2 · secondary NCT05051579
  • -10.1 vs -3.6 36 mg · wk 26 · n 52 · Phase 2 · secondary NCT05051579
  • -9.6 vs -4 12 mg · wk 36 · n 43 · Phase 2 · secondary NCT05051579
  • -8 vs -3.6 12 mg · wk 26 · n 43 · Phase 2 · secondary NCT05051579
  • -13.6 vs -4 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.2 vs -3.6 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • -11.2 vs -4 24 mg · wk 36 · n 49 · Phase 2 · secondary NCT05051579
  • -8.8 vs -3.6 24 mg · wk 26 · n 49 · Phase 2 · secondary NCT05051579
  • -5.8 n 9 · Phase 1 · secondary NCT06023095
  • -11.7 n 9 · Phase 1 · secondary NCT06023095
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Liraglutide (Saxenda): 10 of 10 rows · orforglipron: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Saxenda)
Rows use multiple source trials
orforglipron
Rows use multiple source trials
BMI
absolute change · kg
-1.9 vs 0.15 placebo kg @ 56wk3.0 mga,b,c
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
-2.63 vs -0.21 placebo kg @ 72wk36 mg QDd,a,b,c
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2.83 vs -0.21 placebo kg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-1.94 vs -0.21 placebo kg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
-0.23 vs 0.02 Orlistat mmol/L @ 104wk3.0 mgd,e,a,b,f
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.2 vs 0.02 Orlistat mmol/L @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.22 vs 0.02 Orlistat mmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.5 vs NA placebo mmol/Ld,e,a,b,f
NCT06023095 · Phase 1 · registry result, not featured evidence
show 1 more dose
-0.17 vs NA placebo mmol/L
NCT06023095 · Phase 1 · registry result, not featured evidence
HbA1c
absolute change · percentage points
-0.35% (n=47) vs -0.18% (n=45) Orlistat @ 104wk3.0 mgd,g,h,b,i
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-0.3% (n=36) vs -0.18% (n=45) Orlistat @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.32% (n=46) vs -0.18% (n=45) Orlistat @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-1.66% vs -0.47% placebo @ 72wkorforglipron 17.2 mgg,h,b,i
NCT05872620 · Phase 3 · sponsor-reported, not registry data
3 other source trials
-0.61% (n=57) vs 0.041% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-0.62% (n=60) vs 0.041% (n=60) placebo @ 72wk36 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-0.53% (n=61) vs 0.041% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-2 vs -1 placebo mmHg @ 56wk3.0 mga,b,c
NCT02963935 · Phase 3 · registry result, not featured evidence
-4.36 vs -0.055 placebo mmHg @ 72wk36 mg QDd,a,b,c
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
-3.84 vs -0.055 placebo mmHg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-5.08 vs -0.055 placebo mmHg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
-8.2 vs -3.8 Orlistat kg @ 104wk3.0 mgd,a,b,j
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-5.6 vs -3.8 Orlistat kg @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-6.4 vs -3.8 Orlistat kg @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-5.4 vs -3.8 Orlistat kg @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-4.9 vs -3.8 Orlistat kg @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-14.2 vs -2.4 placebo kg @ 36wk36 mgd,a,b,j
NCT05051579 · Phase 2 · registry result, not featured evidence
show 3 more doses
-9.8 vs -2.4 placebo kg @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-15.4 vs -2.4 placebo kg @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-13.6 vs -2.4 placebo kg @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-6.51 kg @ 104wk3 mgk,a,b,l
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
-4.2 kg @ 4.14wkd,k,a,b,l
NCT05313802 · Phase 1 · registry result, not featured evidence
show 2 more doses
-5.5 kg @ 4.14wk
NCT05313802 · Phase 1 · registry result, not featured evidence
-3.6 kg @ 4.14wk
NCT05313802 · Phase 1 · registry result, not featured evidence
Dropout rate
25%3.0 mgm
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
27.4%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
29.2%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
23.4%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
22.3%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
25.6%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
10.4%3.0 mg
NCT02918279 · Phase 3
22.7%3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
34.8%
NCT03048578 · Phase 4 · registry result, not featured evidence
20.7%3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
10%
NCT02911818 · Phase 4 · registry result, not featured evidence
—
NCT01562678 · Phase 4 · registry result, not featured evidence
0%
NCT03115424 · Phase 3 · registry result, not featured evidence
0%
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
20%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
15%Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
11.8%Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
16.2%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
19.7%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
31.4%
NCT01784965 · Phase 3 · registry result, not featured evidence
8.8%
NCT04883346 · Phase 2 · registry result, not featured evidence
55.2%
NCT03158805 · Phase 2 · registry result, not featured evidence
11.9%
NCT03523273 · Phase 2 · registry result, not featured evidence
10.5%
NCT02647944 · Phase 2 · registry result, not featured evidence
11.8%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
17.8%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
21.5%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
19.4%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
10.5%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
16.7%420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
16.7%AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
12.5%AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT03041792 · Phase 1 · registry result, not featured evidence
10%36 mg QDn
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
8.8%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
11.5%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
12%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
13.2%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
8.3%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
8.5%3.0 mgm
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
9.9%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
9%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
9.2%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
8.5%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
11.1%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT02918279 · Phase 3
—3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
1.1%
NCT03048578 · Phase 4 · registry result, not featured evidence
—3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
—
NCT02911818 · Phase 4 · registry result, not featured evidence
—
NCT01562678 · Phase 4 · registry result, not featured evidence
—
NCT03115424 · Phase 3 · registry result, not featured evidence
—
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
10.9%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
—Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
—Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
7.6%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
8.5%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.9%
NCT01784965 · Phase 3 · registry result, not featured evidence
—
NCT04883346 · Phase 2 · registry result, not featured evidence
—
NCT03158805 · Phase 2 · registry result, not featured evidence
—
NCT03523273 · Phase 2 · registry result, not featured evidence
10.5%
NCT02647944 · Phase 2 · registry result, not featured evidence
5.4%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
5.6%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
9.7%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
3.1%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
4.2%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
—420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
—210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
—70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT03041792 · Phase 1 · registry result, not featured evidence
3.3%36 mg QDn
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
3.5%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
1.6%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
4%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
1.9%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
Serious AEs
4.2%3.0 mgm
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
15.1%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
6.2%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
8.8%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
8.6%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
3.4%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
2.4%3.0 mg
NCT02918279 · Phase 3
16.5%3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
4.5%
NCT03048578 · Phase 4 · registry result, not featured evidence
0%3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
0%
NCT02911818 · Phase 4 · registry result, not featured evidence
0%
NCT01562678 · Phase 4 · registry result, not featured evidence
8.3%
NCT03115424 · Phase 3 · registry result, not featured evidence
0%
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
0%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
5%Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
11.8%Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
8.2%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
4.2%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.9%
NCT01784965 · Phase 3 · registry result, not featured evidence
0%
NCT04883346 · Phase 2 · registry result, not featured evidence
0%
NCT03158805 · Phase 2 · registry result, not featured evidence
1.5%
NCT03523273 · Phase 2 · registry result, not featured evidence
0%
NCT02647944 · Phase 2 · registry result, not featured evidence
10.8%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
11.1%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
7.5%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
6.1%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
9.5%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
0%420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%
NCT03041792 · Phase 1 · registry result, not featured evidence
10%36 mg QDn
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
5.3%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
1.6%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
0%36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
10.3%36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
3.8%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.6%36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.5%6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.5%5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
2%tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
5.3%12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
2.2%36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
2.2%20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
3.0 mgm
nausea 47.6% (placebo 17.1%)
constipation 26.9% (placebo 12.4%)
diarrhoea 17.9% (placebo 12.4%)
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
3.0 mg
nausea 40.8% (placebo 17%)
nasopharyngitis 26.5% (placebo 27.8%)
diarrhoea 25.5% (placebo 14.2%)
NCT01272219 · Phase 3 · Obesity · phase 3
3.0 mg
nausea 43.7% (placebo 17%)
constipation 21.2% (placebo 11.3%)
diarrhoea 21% (placebo 14.2%)
NCT01272219 · Phase 3 · Obesity · phase 3
3.0 mg
hypoglycaemia 44.3% (placebo 27.8%)
nausea 32.7% (placebo 13.7%)
diarrhoea 25.6% (placebo 12.7%)
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
1.8 mg
hypoglycaemia 40% (placebo 27.8%)
nausea 31.4% (placebo 13.7%)
diarrhoea 17.6% (placebo 12.7%)
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
3.0 mg
nausea 26.7% (placebo 6.7%)
diarrhoea 16.5% (placebo 7.8%)
headache 14.2% (placebo 11.2%)
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
3.0 mg
nausea 42.4% (placebo 14.3%)
vomiting 34.4% (placebo 4%)
nasopharyngitis 27.2% (placebo 30.2%)
NCT02918279 · Phase 3
3 mg
nausea 41.9%
gastrointestinal hypomotility 35.8%
diarrhoea 27.7%
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
nausea 23.6% (placebo 7%)
constipation 15.7% (placebo 9.3%)
abdominal pain 9% (placebo 2.3%)
NCT03048578 · Phase 4 · registry result, not featured evidence
3.0 mg
gi related 46.7% (placebo 12.9%)
respiratory tract infection 10.9% (placebo 15.1%)
injection site reaction 7.6% (placebo 8.6%)
NCT03038620 · Phase 4 · registry result, not featured evidence
nausea 36% (placebo 4.3%)
upper respiratory infection 32% (placebo 8.7%)
constipation 30% (placebo 0%)
NCT02911818 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 25%)
NCT01562678 · Phase 4 · registry result, not featured evidence
nausea 16.7% (placebo 11.1%)
vomiting 16.7% (placebo 11.1%)
hgb < 11.5 g/dl 0% (placebo 0%)
NCT03115424 · Phase 3 · registry result, not featured evidence
during study 24.7% (placebo 25%)
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
3 mg
nausea 25.5% (placebo 11.1%)
vomiting 9.1% (placebo 0%)
diarrhea 7.3% (placebo 0%)
NCT03480022 · Phase 3 · registry result, not featured evidence
diarrhoea 50% (placebo 16.7%)
abdominal pain 30% (placebo 25%)
constipation 15% (placebo 0%)
NCT02527200 · Phase 3 · registry result, not featured evidence
diarrhoea 41.2% (placebo 16.7%)
abdominal pain 17.6% (placebo 25%)
abdominal pain upper 17.6% (placebo 0%)
NCT02527200 · Phase 3 · registry result, not featured evidence
3.0 mg
nausea 29.7% (placebo 11.7%)
diarrhoea 23.1% (placebo 15.2%)
nasopharyngitis 21.5% (placebo 18.3%)
NCT02963922 · Phase 3 · registry result, not featured evidence
3.0 mg
nausea 47.9% (placebo 17.9%)
constipation 30.3% (placebo 18.6%)
vomiting 23.2% (placebo 5%)
NCT02963935 · Phase 3 · registry result, not featured evidence
elective back surgery 2.9% (placebo 0%)
family issues 2.9% (placebo 0%)
protocol deviation 2.9% (placebo 0%)
NCT01784965 · Phase 3 · registry result, not featured evidence
dyspepsia 23.5%
constipation 11.8%
fatigue 11.8%
NCT04883346 · Phase 2 · registry result, not featured evidence
nausea 65.5% (placebo 45.2%)
constipation 41.4% (placebo 9.7%)
heartburn 34.5% (placebo 6.5%)
NCT03158805 · Phase 2 · registry result, not featured evidence
nausea 59.7% (placebo 15.9%)
diarrhea 34.3% (placebo 8.7%)
abdominal pain/discomfort 28.4% (placebo 5.8%)
NCT03523273 · Phase 2 · registry result, not featured evidence
nausea 63.2% (placebo 9.5%)
headache 26.3% (placebo 19%)
abdominal pain/discomfort 21.1% (placebo 9.5%)
NCT02647944 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 50.5%
nasopharyngitis 40.9%
headache 23.7%
NCT00422058 · Phase 2 · registry result, not featured evidence
1.8 mg / 3.0 mg
nasopharyngitis 37.8%
nausea 37.8%
gastroenteritis 22.2%
NCT00422058 · Phase 2 · registry result, not featured evidence
2.4 mg / 3.0 mg
nasopharyngitis 45.2%
nausea 41.9%
headache 24.7%
NCT00422058 · Phase 2 · registry result, not featured evidence
placebo / 2.4 mg / 3.0 mg
nasopharyngitis 41.8%
nausea 29.6%
headache 23.5%
NCT00422058 · Phase 2 · registry result, not featured evidence
1.2 mg / 3.0 mg
nasopharyngitis 38.9%
nausea 36.8%
influenza 25.3%
NCT00422058 · Phase 2 · registry result, not featured evidence
420 mg
abdominal pain 0% (placebo 0%)
arthralgia 0% (placebo 0%)
back pain 0% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
nausea 50% (placebo 0%)
diarrhoea 33.3% (placebo 0%)
upper respiratory tract infection 33.3% (placebo 16.7%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
210 mg
upper respiratory tract infection 50% (placebo 16.7%)
arthralgia 16.7% (placebo 0%)
blood creatine phosphokinase increased 16.7% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
upper respiratory tract infection 66.7% (placebo 16.7%)
constipation 33.3% (placebo 0%)
early satiety 33.3% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
70 mg
back pain 16.7% (placebo 0%)
constipation 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
decreased appetite 62.5% (placebo 0%)
lipase increased 37.5% (placebo 0%)
nausea 25% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
nausea 46.9% (placebo 3.6%)
diarrhoea 34.4% (placebo 14.3%)
headache 34.4% (placebo 10.7%)
NCT03041792 · Phase 1 · registry result, not featured evidence
36 mg QDn
nausea 33.3% (placebo 0%)
constipation 31.7% (placebo 8.3%)
nasopharyngitis 20% (placebo 35%)
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
12 mg QD
nasopharyngitis 42.1% (placebo 35%)
constipation 28.1% (placebo 8.3%)
nausea 15.8% (placebo 0%)
NCT05931380 · Phase 3 · registry result, not featured evidence
6 mg QD
constipation 36.1% (placebo 8.3%)
nasopharyngitis 26.2% (placebo 35%)
diarrhoea 14.8% (placebo 3.3%)
NCT05931380 · Phase 3 · registry result, not featured evidence
36 mg
nausea 41.4% (placebo 10%)
constipation 27.6% (placebo 6%)
vomiting 27.6% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
36 mg
nausea 48.3% (placebo 10%)
constipation 24.1% (placebo 6%)
covid-19 24.1% (placebo 18%)
NCT05051579 · Phase 2 · registry result, not featured evidence
12 mg
nausea 50% (placebo 10%)
vomiting 26% (placebo 6%)
constipation 24% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
45 mg
nausea 41.9% (placebo 10%)
vomiting 29% (placebo 6%)
constipation 19.4% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
45 mg
nausea 36.7% (placebo 10%)
diarrhoea 33.3% (placebo 10%)
vomiting 26.7% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
24 mg
nausea 58.5% (placebo 10%)
diarrhoea 35.8% (placebo 10%)
constipation 32.1% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
17.2 mg tablet QD
vomiting 5.7%
headache 3.4%
nausea 3.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
36 mg capsule QD
headache 6.7%
constipation 4.4%
dizziness 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
36 mg capsule QD
headache 15.9%
vomiting 10.8%
diarrhoea 6.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
12 mg capsule QD
constipation 6%
nausea 6%
headache 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
12 mg capsule QD
constipation 21%
headache 19.4%
nausea 17.2%
NCT06440980 · Phase 1 · registry result, not featured evidence
6 mg capsule QD
headache 8.7%
dyspepsia 4.3%
vomiting 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
6 mg capsule QD
headache 12.3%
nausea 9.4%
dyspepsia 7.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
24 mg capsule QD
headache 10%
vomiting 6%
abdominal pain 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
24 mg capsule QD
nausea 17.1%
diarrhoea 12.7%
constipation 10.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
14.5 mg tablet QD
headache 8.3%
nausea 8.3%
diarrhoea 6.7%
NCT06440980 · Phase 1 · registry result, not featured evidence
9 mg tablet QD
headache 9.7%
constipation 9.1%
vomiting 8.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
5.5 mg tablet QD
headache 8.4%
nausea 8.4%
constipation 4.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
3 mg capsule QD
nausea 4.3%
decreased appetite 2.1%
diarrhoea 2.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
3 mg capsule QD
headache 17.6%
nausea 13.8%
constipation 9.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
2.5 mg tablet QD
headache 8.1%
constipation 6.2%
nausea 6.2%
NCT06440980 · Phase 1 · registry result, not featured evidence
1 mg capsule QD
constipation 7.7%
decreased appetite 1.9%
eructation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
1 mg capsule QD
constipation 27%
headache 15.8%
nausea 6%
NCT06440980 · Phase 1 · registry result, not featured evidence
0.8 mg tablet QD
constipation 8.9%
headache 8.9%
dyspepsia 4.7%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 1)
constipation 9.6%
diarrhoea 1.9%
eructation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 2)
abdominal pain 3.8%
diarrhoea 3.8%
constipation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 3)
constipation 13.5%
abdominal distension 1.9%
dizziness 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 4)
nausea 7.8%
vomiting 7.8%
constipation 5.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 5)
nausea 8.3%
dyspepsia 6.3%
headache 6.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 6)
diarrhoea 5.9%
abdominal pain 3.9%
constipation 3.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 7)
nausea 6.5%
dyspepsia 4.3%
headache 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 8)
dyspepsia 6.4%
headache 4.3%
nausea 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 9)
nausea 10.9%
abdominal distension 6.5%
abdominal pain 6.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 10)
constipation 8%
diarrhoea 6%
dyspepsia 6%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 12)
nausea 8%
headache 6%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 13)
constipation 8.2%
abdominal pain 4.1%
diarrhoea 4.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 14)
dizziness 12.2%
headache 6.1%
abdominal pain 4.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 15)
nausea 8%
constipation 4%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 16)
heart rate increased 8.9%
constipation 4.4%
headache 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 18)
constipation 6.7%
diarrhoea 6.7%
nausea 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 11)
dyspepsia 6%
constipation 4%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 17)
nausea 13.3%
headache 6.7%
diarrhoea 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
decreased appetite 70% (placebo 50%)
diarrhoea 60% (placebo 25%)
eructation 40% (placebo 0%)
NCT06023095 · Phase 1 · registry result, not featured evidence
nausea 80% (placebo 0%)
decreased appetite 70% (placebo 50%)
diarrhoea 70% (placebo 25%)
NCT06023095 · Phase 1 · registry result, not featured evidence
36 mg
constipation 4.5%
diarrhoea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain upper 4.5%
dizziness 4.5%
vomiting 4.5%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
back pain 4.5%
diarrhoea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
constipation 23.1%
nausea 11.5%
abdominal pain 7.7%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
constipation 22.2%
alopecia 5.6%
diarrhoea 5.6%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
anxiety 6.3%
constipation 6.3%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
12 mg QD
alanine aminotransferase increased 3.8%
aspartate aminotransferase increased 3.8%
fatigue 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
12 mg QD
back pain 5.3%
constipation 5.3%
cough 5.3%
NCT06186622 · Phase 1 · registry result, not featured evidence
6 mg QD
dyspepsia 7.7%
nausea 7.7%
diarrhoea 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
6 mg QD
fatigue 15.8%
eructation 10.5%
headache 10.5%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg + 0.2 mg
dizziness 4.8%
headache 4.8%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 0.25 mg
nausea 9.1%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
decreased appetite 4.5%
headache 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 1000 mg
headache 4.5%
nausea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 0.25 mg
constipation 6.3%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain upper 6.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
dysmenorrhoea 6.3%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
24 mg QD
abdominal pain 3.8%
diarrhoea 3.8%
headache 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
24 mg QD
constipation 5.6%
diarrhoea 5.6%
eructation 5.6%
NCT06186622 · Phase 1 · registry result, not featured evidence
20 mg + 20 mg
alanine aminotransferase increased 9.1%
aspartate aminotransferase increased 9.1%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
20 mg + 20 mg
alanine aminotransferase increased 12.5%
aspartate aminotransferase increased 12.5%
headache 6.3%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
3 mg QD
diarrhoea 3.8%
fatigue 3.8%
nausea 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
3 mg QD
abdominal pain 10%
nausea 10%
alanine aminotransferase increased 5%
NCT06186622 · Phase 1 · registry result, not featured evidence
1 mg QD
medication error 7.4%
dysmenorrhoea 3.7%
fatigue 3.7%
NCT06186622 · Phase 1 · registry result, not featured evidence
1 mg + 1000 mg
headache 3.7%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
1 mg QD
eructation 15%
decreased appetite 10%
headache 10%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg capsule
nausea 9.5%
abdominal pain 4.8%
constipation 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg capsule
diarrhoea 4.4%
abdominal pain 2.2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg DF capsule
constipation 8.3%
diarrhoea 8.3%
nausea 8.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg EPB capsule
nausea 41.7%
headache 16.7%
diarrhoea 8.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
60 mg tablet
vomiting 14.3%
constipation 4.8%
dyspepsia 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
45 mg tablet
abdominal distension 9.5%
nausea 9.5%
vomiting 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
37.5 mg tablet
headache 19%
nausea 19%
constipation 9.5%
NCT05841238 · Phase 1 · registry result, not featured evidence
37.5 mg tablet
nausea 14.6%
headache 12.2%
vomiting 12.2%
NCT05841238 · Phase 1 · registry result, not featured evidence
35 mg tablet
dyspepsia 14.3%
flatulence 14.3%
nausea 14.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
35 mg tablet
intertrigo 14.3%
abdominal distension 0%
abdominal pain 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
20 mg tablet
dyspepsia 4.3%
abdominal pain 2.2%
diarrhoea 2.2%
NCT05841238 · Phase 1 · registry result, not featured evidence
16 mg capsule
diarrhoea 6.5%
vomiting 2.2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
10 mg tablet
constipation 12.2%
nausea 4.1%
dyspepsia 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
8 mg capsule
dyspepsia 10.2%
decreased appetite 6.1%
diarrhoea 6.1%
NCT05841238 · Phase 1 · registry result, not featured evidence
5 mg tablet
headache 12%
dyspepsia 4%
abdominal pain 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
2.5 mg tablet
headache 4%
decreased appetite 2%
gastrooesophageal reflux disease 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
2 mg capsule
constipation 10%
diarrhoea 2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
0.8 mg tablet
constipation 3.8%
headache 3.8%
nausea 3.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
constipation 37.5%
headache 33.3%
weight decreased 25%
NCT05313802 · Phase 1 · registry result, not featured evidence
dyspepsia 41.7%
constipation 33.3%
weight decreased 29.2%
NCT05313802 · Phase 1 · registry result, not featured evidence
constipation 25%
dyspepsia 25%
headache 16.7%
NCT05313802 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 72 weeks versus 56 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 1 versus Phase 2.
  6. fThe assessment timepoint is not available for both results.
  7. gTrial phases differ: Phase 3 versus Phase 2.
  8. hPopulation context differs: registered conditions differ.
  9. iAssessment timepoints differ: 72 weeks versus 104 weeks.
  10. jAssessment timepoints differ: 36 weeks versus 104 weeks.
  11. kTrial phases differ: Phase 1 versus Phase 4.
  12. lAssessment timepoints differ: 4.14 weeks versus 104 weeks.
  13. mPopulation comparability has not been reviewed for 30 of these studies.
  14. nPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Saxenda)

Weight Loss Maintenance 80.8% (n=194) vs 47.9% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Regain 5% 1.9% (n=207) vs 17.5% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Regain 10% 0% (n=207) vs 2.9% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss Maintenance 50% 93.2% (n=207) vs 70.9% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss Maintenance 75% 87.4% (n=207) vs 54.4% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Triglycerides 0.02 vs 0.12 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.19 vs -0.01 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
LDL-C 0.24 vs 0.33 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.01 vs -0.01 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
Total Cholesterol 0.22 vs 0.33 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.01 vs 0 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
Metabolic Syndrome 31.4% (n=194) vs 36.7% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
HOMA-B 8.51% (n=190) vs 6.16% (n=181) placebo @ 56wk3.0 mg
percent change · % of baseline
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
HOMA-IR -0.01 vs 0.08 placebo ratio @ 56wk3.0 mg
absolute change · ratio
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 6 more results
1.57 vs 0.8 placebo ratio @ 16wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.43 vs 0.8 placebo ratio @ 16wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.51 vs 0.8 placebo ratio @ 16wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
2.26 vs 0.88 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.45 vs 0.88 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.9 vs 0.88 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
Fasting Insulin 0.5 vs 2.35 placebo pmol/L @ 56wk3.0 mg
absolute change · pmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 10 more results
-12.3 vs -16.7 Orlistat pmol/L @ 20wk3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-19.6 vs -15.3 Orlistat pmol/L @ 104wk3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.7 vs -16.7 Orlistat pmol/L @ 20wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
18.6 vs -15.3 Orlistat pmol/L @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-15 vs -16.7 Orlistat pmol/L @ 20wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-3.9 vs -16.7 Orlistat pmol/L @ 20wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
0.7 vs -15.3 Orlistat pmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-2.1 vs -15.3 Orlistat pmol/L @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
8.7 vs -16.7 Orlistat pmol/L @ 20wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-13.5 vs -15.3 Orlistat pmol/L @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence

+ 179 further endpoints in the CSV export.

orforglipron

Weight Loss 15% 18.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
22.81% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
9.84% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Weight Loss 20% 8.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
12.28% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
3.28% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 6 5 78.57% (n=14) vs 0% (n=14) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
45.45% (n=11) vs 0% (n=14) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
31.25% (n=16) vs 0% (n=14) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
VAT Change Cm2 -49.3 vs -7.2 placebo cm @ 72wk36 mg QD
absolute change · cm
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-52.3 vs -7.2 placebo cm @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-47.5 vs -7.2 placebo cm @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Non-HDL-C -10.75% (n=60) vs 0.05% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-10.2% (n=57) vs 0.05% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-6.91% (n=61) vs 0.05% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
HDL-C 5.17% (n=60) vs 7.37% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
8.62% (n=57) vs 7.37% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
5.75% (n=61) vs 7.37% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
TG -15.64% (n=60) vs -9.61% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-24.85% (n=57) vs -9.61% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-16.85% (n=61) vs -9.61% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Fasting Glucose Change mg/dL -17.79 vs -0.31 placebo mg @ 72wk36 mg QD
absolute change · mg
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-15.5 vs -0.31 placebo mg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-13.98 vs -0.31 placebo mg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
IWQOL-Lite-CT Physical Function 2.51 vs -0.43 placebo score @ 72wk36 mg QD
absolute change · score
Physical Function Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
3.08 vs -0.43 placebo score @ 72wk12 mg QD
Physical Function Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
3.71 vs -0.43 placebo score @ 72wk6 mg QD
Physical Function Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
IWQoL-Lite CT Psychosocial 4.02 vs 1.74 placebo score @ 72wk36 mg QD
absolute change · score
Psychosocial Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
5.41 vs 1.74 placebo score @ 72wk12 mg QD
Psychosocial Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
3.47 vs 1.74 placebo score @ 72wk6 mg QD
Psychosocial Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Saxenda)'s landscape · orforglipron's landscape